

	<i>pT3-4 disease</i>		<i>GS 7 or more</i>		<i>Primary Gleason pattern 4</i>	
	p	OR (95% CI)	p	OR (95% CI)	p value	OR (95% CI)
<b>Univariate analysis</b>						
Volume >50	0.397	0.71	0.002	0.43	<0.001	0.18
No	14.2%	(0.32-1.57)	50.0%	(0.25-0.73)	18.9%	(0.06-0.50)
Yes	10.5%		29.8%		4.0%	
PSAD >0.15	0.392	0.66	0.002	2.55	0.005	3.19
No	13.3%	(0.26-1.71)	32.7%	(1.42-4.6)	7.2%	(1.37-7.42)
Yes	9.2%		55.4%		20.0%	
BMI >30 :	0.004	4.08	0.364	1.43	0.642	1.31
No	9.5%	(1.64-10.17)	38.0%	(0.66-3.09)	10.5%	(0.42-4.12)
Yes	30.0%		46.7%		13.3%	
<b>Multivariate analysis</b>						
<i>Overall cohort : PSA ≤10, T1c, biopsy Gleason score 6, &lt;3 positive cores, &lt;50% cancer involvement (n=230)</i>						
Volume >50	0.121	0.488	0.052	0.545	0.008	0.224
		(0.20-1.21)		(0.30-1.00)		(0.074-0.680)
PSAD >0.15	0.233	0.525	0.043	1.985	0.244	1.748
		(0.18-1.52)		(1.02-3.86)		(0.68-4.47)
BMI >30	0.003	4.192	0.185	1.722	0.388	1.774
		(1.65-10.64)		(0.77-3.84)		(0.51-5.72)
<i>Restricted cohort : PSA ≤10, T1c, biopsy Gleason score 6, &lt;3 positive cores, &lt;50% cancer involvement, PSAD &lt;0.15 (n=165)</i>						
Volume >50	0.229	0.559	0.129	0.584	0.010	0.186
		(0.22-1.44)		(0.29-1.17)		(0.05-0.66)
BMI >30	0.019	3.472	0.160	1.877	0.218	2.49
		(1.23-9.83)		(0.78-4.51)		(0.58-10.62)